Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease

In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A2AReceptor Antagonist/Inverse Agonist

(2023) Yutaro Ohno et al.   MOLECULAR PHARMACOLOGY

Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets

(2023) Yutaro Ohno et al.   European Journal of Pharmacology

The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease

(2022) Akihisa Mori et al.   MOLECULES

Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease

(2021) Peter Jenner et al.   Expert Review of Neurotherapeutics

Parkinson's disease

(2021) Bastiaan R Bloem et al.   LANCET

Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary

(2021) Tamara Pringsheim et al.   NEUROLOGY

Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update

(2020) Paulina Gonzalez-Latapi et al.   CNS DRUGS

Non-motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life

(2018) X. Huang et al.   EUROPEAN JOURNAL OF NEUROLOGY

The Emerging Evidence of the Parkinson Pandemic

(2018) E. Ray Dorsey et al.   Journal of Parkinsons Disease

Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2017) Valery L Feigin et al.   LANCET NEUROLOGY

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

(2017) Fabrizio Stocchi et al.   NEUROLOGY

Long-term effects of rasagiline and the natural history of treated Parkinson's disease

(2016) Olivier Rascol et al.   MOVEMENT DISORDERS

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

(2013) C. Warren Olanow et al.   MOVEMENT DISORDERS

Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

(2012) J. J. Ferreira et al.   EUROPEAN JOURNAL OF NEUROLOGY

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

(2011) Olivier Rascol et al.   LANCET NEUROLOGY

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

(2011) A. F. Ramlackhansingh et al.   NEUROLOGY

Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients

(2011) Masahiro Mishina et al.   PLoS One

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

(2009) Angelo Antonini et al.   LANCET NEUROLOGY

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Target site occupancy: Emerging generalizations from clinical and preclinical studies

(2009) Sarah Grimwood et al.   PHARMACOLOGY & THERAPEUTICS

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS